Seattle genetics announces u.s. fda grants breakthrough therapy designation for tucatinib

Seattle genetics announces u.s. fda grants breakthrough therapy designation for tucatinib in locally advanced or metastatic her2-positive breast cancer.seattle genetics inc - intend to submit a new drug application for tucatinib to fda and an maa to the ema by q1 2020.
SGEN Ratings Summary
SGEN Quant Ranking